Ascendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $158.00 by Analysts at Citigroup

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) had its price target lowered by research analysts at Citigroup from $187.00 to $158.00 in a research report issued on Thursday, The Fly reports. Citigroup’s price target indicates a potential upside of 102.36% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. SVB Leerink lifted their price objective on shares of Ascendis Pharma A/S from $190.00 to $193.00 and gave the company an “outperform” rating in a research report on Tuesday, March 15th. Wedbush reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Monday, March 28th. Zacks Investment Research downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Monday, January 17th. Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $170.00 to $190.00 in a research note on Monday, March 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Ascendis Pharma A/S in a research note on Friday, April 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Buy” and a consensus price target of $162.09.

Ascendis Pharma A/S stock opened at $78.08 on Thursday. The company has a market cap of $4.45 billion, a P/E ratio of -9.42 and a beta of 0.86. Ascendis Pharma A/S has a 1-year low of $75.70 and a 1-year high of $178.71. The company has a fifty day simple moving average of $106.85 and a 200 day simple moving average of $123.42.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last announced its quarterly earnings data on Wednesday, May 11th. The biotechnology company reported ($2.21) EPS for the quarter, beating analysts’ consensus estimates of ($2.25) by $0.04. Ascendis Pharma A/S had a negative net margin of 5,015.63% and a negative return on equity of 45.19%. During the same period in the prior year, the firm posted ($1.41) earnings per share. As a group, analysts predict that Ascendis Pharma A/S will post -8.95 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of ASND. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $31,000. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of Ascendis Pharma A/S by 51.2% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 195 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 66 shares in the last quarter. CI Investments Inc. acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $37,000. Barclays PLC raised its position in shares of Ascendis Pharma A/S by 117.5% in the 4th quarter. Barclays PLC now owns 627 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 4,218 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Ascendis Pharma A/S by 17.8% in the 1st quarter. SG Americas Securities LLC now owns 942 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 142 shares in the last quarter.

Ascendis Pharma A/S Company Profile (Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Further Reading

The Fly logo

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.